BioSpace News Archive

Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology

QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status

Progressive Care Inc., a personalized healthcare services and technology company, announced that it has sold through over 90% of its COVID-19 Antibody testing kits.

JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China , Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition to royalties on sales SAN FRANCISCO and TAIPEI, Taiwan, July 14, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) technology platform and JW Therapeutics, a biotechnology company focusing on the

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib

MyndTec Inc., an award-winning Canadian medical technology company, and University of Health Network (UHN), Canada’s largest medical research hospital, have announced the extension of an exclusive license agreement.

Medicago expects to enroll 180 healthy adult participants Preliminary safety and immunogenicity results are expected in October 2020 Dynavax is providing CpG 1018, the adjuvant contained in its U.S. FDA-approved adult hepatitis B vaccine, to enhance the immune response of Medicago’s COVID-19 vaccine candidate

To stem the spread of the COVID-19 virus in the midst of a spike in the number of cases and hospitalizations, the State of Arizona recently awarded Phoenix-based concierge phlebotomy services pioneer Vestra Labs a contract to provide virus testing at 148 skilled nursing facilities throughout the state.

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz , MD, FACP, has been appointed to its Board of Directors. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect Corporation and brings

In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis